medigraphic.com
ISSN 2007-6800 (Impreso)

2020, Número S1

<< Anterior Siguiente >>

Rev Mex Traspl 2020; 9 (S1)


Alteraciones del metabolismo de la glucosa en donante y receptor

Martínez-Juárez IA

Idioma: Español
Referencias bibliográficas: 48
Paginas: 99-103
Archivo PDF: 222.62 Kb.


FRAGMENTO

De los 415 millones de personas diagnosticadas con DM2, 80% habitan en países de bajos recursos. México tiene 11.5 millones de habitantes con DM2 y se encuentra dentro de los primeros 10 países con mayor número de casos.
Los donadores vivos tienen seis veces más riesgo de ERC (enfermedad renal crónica) a 15 años en comparación con población sana, pero el riesgo acumulado se mantiene por debajo de 1% (riesgo absoluto de ERC a lo largo de su vida es 14 casos por 10,000 habitantes en población sana, 90 casos por 10,000 habitantes en donadores renales y 326 casos por 10,000 habitantes en población general).
La incidencia de diabetes postnefrectomía ha sido estudiada en diferentes grupos étnicos, se ha descubierto que la comunidad hispano latina tiene 2.5 más riesgo de desarrollar diabetes posterior a la donación renal.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Grams ME, Sang Y, Levey AS et al. Kidney-failure risk projection for the living kidney-donor candidate. N Engl J Med. 2016; 374: 411-421.

  2. Spanish Society of Nephrology (SEN) and Spanish Transplant Organization (ONT). Recommendations for living-donor kidney transplantation. Nefrologia. 2010; 30: 1-105.

  3. Boudville N, Isbel N. The CARI guidelines. Donors at risk: impaired glucose tolerance. Nephrology (Carlton). 2010; 15 (Suppl 1): S133-S136.

  4. Andrews PA, Burnapp L, Manas D et al. Summary of the British Transplantation Society/Renal Association U.K. Guidelines for living donor kidney transplantation. Transplantation. 2012; 93: 666-673.

  5. Dudley C, Harden P. Renal Association Clinical Practice Guideline on the assessment of the potential kidney transplant recipient. Nephron Clin Pract. 2011; 118: s209-s224.

  6. Morris RD, Rimm DL, Hartz AJ et al. Obesity and heredity in the etiology of non-insulin-dependent diabetes mellitus in 32 662 adult white women. Am J Epidemiol. 1989; 130: 112-122.

  7. Lentine KL, Kasiske BL, Levey AS et al. KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation. 2017; 101 (8S Suppl 1): S1-S109.

  8. Pascual J, Abramowicz D, Cochat P et al. European renal best practice guideline on the management and evaluation of the kidney donor and recipient. Nefrologia. 2014; 34: 293-301.

  9. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007; 30: 753-759.

  10. Bello-Chavolla OY, Rojas-Martinez R, Aguilar-Salinas CA, Hernández-Avila M. Epidemiology of diabetes mellitus in Mexico. Nutr Rev. 2017; 75 (suppl 1): 4-12.

  11. Wareham NJ, Byrne CD, Williams R et al. Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care. 1999; 22: 262-270.

  12. Vigneault CB, Asch WS, Dahl NK, Bia MJ. Should living kidney donor candidates with impaired fasting glucose donate? Clin J Am Soc Nephrol. 2011; 6 (8): 2054-2059.

  13. Okamoto M, Suzuki T, Fujiki M et al. The consequences for live kidney donors with preexisting glucose intolerance without diabetic complication: analysis at a single Japanese center. Transplantation. 2010; 89: 1391-1395.

  14. Shinzato T, Kurosawa A, Kubo T et al. No significant differences in short-term renal prognosis between living kidney donors with and without diabetes. Clin Exp Nephrol. 2018; 22 (3): 694-701.

  15. Feig DS, Zinman B, Wang X, Hux JE. Risk of development of diabetes mellitus after diagnosis of gestational diabetes. CMAJ. 2008; 179 (3): 229-234.

  16. Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003; 26: 725-731.

  17. Lorenzo C, Hazuda HP, Haffner SM. Insulin resistance and excess risk of diabetes in Mexican-Americans: the San Antonio Heart Study. J Clin Endocrinol Metab. 2012; 97 (3): 793-799.

  18. Lam NN, Lentine KL, Levey AS, Kasiske BL, Garg AX. Long-term medical risks to the living kidney donor. Nat Rev Nephrol. 2015; 11 (7): 411-419.

  19. Muzaale AD, Massie AB, Wang MC et al. Risk of end-stage renal dis- ease following live kidney donation. JAMA. 2014; 311: 579-586.

  20. Holscher CM, Bae S, Thomas AG et al. Early hypertension and diabetes after living kidney donation: a national cohort study. Transplantation. 2019; 103 (6): 1216-1223.

  21. Alegre-Díaz J, Herrington W, López-Cervantes M et al. Diabetes and cause-specific mortality in Mexico City. N Engl J Med. 2016; 375 (20): 1961-1971.

  22. Lopes GS, Lemos CC, Mandarim-De-Lacerda CA, Bregman R. Effect of unilateral nephrectomy on renal function of diabetic rats. Histol Histopathol. 2004; 19: 1085-1088.

  23. Garg AX, Muirhead N, Knoll G et al. Proteinuria and reduced kidney function in living kidney donors: a systematic review, meta-analysis, and meta-regression. Kidney Int. 2006; 70: 1801-1810.

  24. Iwai T, Miyazaki M, Yamada G et al. Diabetes mellitus as a cause or comorbidity of chronic kidney disease and its outcomes: the Gonryo study. Clin Exp Nephrol. 2018; 22 (2): 328-336.

  25. Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017; 12 (12): 2032-2045.

  26. Sharif A, Hecking M, de Vries AP et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant. 2014; 14 (9): 1992-2000.

  27. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001; 344: 1608-1621.

  28. Papanas N, Liakopoulos V, Maltezos E, Stefanidis I. The diabetic foot in end stage renal disease. Ren Fail. 2007; 29 (5): 519-528.

  29. Ceresa CD, Aitken E, Dempster NJ, Kingsmore D. Outcomes of renal transplantation in patients with major lower limb amputation. Transplant Proc. 2014; 46 (1): 115-120.

  30. Aitken E, Ramjug S, Buist L, Kingsmore D. The prognostic significance of iliac vessel calcification in renal transplantation. Transplant Proc. 2012; 44 (10): 2925-2931.

  31. Baker RJ, Mark PB, Patel RK, Stevens KK, Palmer N. Renal association clinical practice guideline in post-operative care in the kidney transplant recipient. BMC Nephrol. 2017; 18 (1): 174.

  32. Zelle DM, Corpeleijn E, Deinum J et al. Pancreatic beta-cell dysfunction and risk of new-onset diabetes after kidney transplantation. Diabetes Care. 2013; 36: 1926-1932.

  33. Kervinen MH, Lehto S, Helve J, Grönhagen-Riska C, Finne P. Type 2 diabetic patients on renal replacement therapy: probability to receive renal transplantation and survival after transplantation. PLoS One. 2018; 13 (8): e0201478.

  34. Sharif A, Baboolal K. Complications associated with new-onset diabetes after kidney transplantation. Nat Rev Nephrol. 2011; 8 (1): 34-42.

  35. Shivaswamy V, Boerner B, Larsen J. Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes. Endocr Rev. 2016; 37 (1): 37-61. doi: 10.1210/er.2015-1084.

  36. Cai R, Wu M, Lin M, Guo X, Xing Y. Pretransplant homeostasis model assessment of insulin resistance and fasting plasma glucose predict new-onset diabetes after renal transplant in chinese patients. Transplant Proc. 2019; 51 (3): 768-773.

  37. Morgan RD, O’Callaghan JM, Knight SR, Morris PJ. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. Transplantation. 2012; 93 (12): 1179-1188.

  38. Cole EH, Johnston O, Rose CL, Gill JS. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol. 2008; 3 (3): 814-821.

  39. Cooper L, Oz N, Fishman G et al. New onset diabetes after kidney transplantation is associated with increased mortality-A retrospective cohort study. Diabetes Metab Res Rev. 2017; 33 (8). doi: 10.1002/dmrr.2920.

  40. Ghisdal L, Bouchta NB, Broeders N et al. Conversion from tacrolimus to cyclosporine A for new- onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature. Transplant Int. 2008; 21: 146-151.

  41. Sharif A, Shabir S, Chand S, Cockwell P, Ball S, Borrows R. Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol. 2011; 22 (11): 2107-2718.

  42. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol. 2008; 19: 1411-1418.

  43. Kleinsteuber A, Halleck F, Khadzhynov D et al. Impact of pre-existing comorbidities on long-term outcomes in kidney transplant recipients. Transplant Proc. 2018; 50 (10): 3232-3241.

  44. Johal S, Jackson-Spence F, Gillott H et al. Pre-existing diabetes is a risk factor for increased rates of cellular rejection after kidney transplantation: an observational cohort study. Diabet Med. 2017; 34 (8): 1067-1073.

  45. He X, Johnston A. Early acute rejection does not affect chronic allograft nephropathy and death censored graft failure. Transplant Proc. 2004; 36 (10): 2993-2996.

  46. Woodle ES, First MR, Pirsch J, Shihab F et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008; 248 (4): 564-77. doi: 10.1097/SLA.0b013e318187d1da.

  47. Woodle E, Clark S, Stewart D et al. Fifteen year outcomes in the astellas double blind randomized controlled trial (RCT) comparing early corticosteroid withdrawal (CSWD) and long-term corticosteroid therapy continuation (CCS) in kidney transplantation [abstract]. Am J Transplant. 2019; 19 (suppl 3).

  48. Pascual J, Galeano C, Royuela A, Zamora J. A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation. Transplantation. 2010; 90 (4): 343-349.




2020     |     www.medigraphic.com